Benzoporphyrin derivative could lead to new treatment for systemic diseases

Abstract

Prospects for a more successful photodynamic therapy for cancer are increasing as early trials with benzoporphyrin derivative [BPD] produce encouraging results. This new drug has several advantages over the existing product, Photofrin®. But the therapeutic goals for BPD do not stop there. Researchers from Quadra Logic Technologies hope to develop a whole new mode of therapy for systemic diseases based on its properties. At the IBC conference, Drug Delivery and Targeting Systems, in London, UK, delegates were told of this latest development.